NO20073104L - Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser - Google Patents
Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelserInfo
- Publication number
- NO20073104L NO20073104L NO20073104A NO20073104A NO20073104L NO 20073104 L NO20073104 L NO 20073104L NO 20073104 A NO20073104 A NO 20073104A NO 20073104 A NO20073104 A NO 20073104A NO 20073104 L NO20073104 L NO 20073104L
- Authority
- NO
- Norway
- Prior art keywords
- agonist
- prevention
- treatment
- neurodegenerative disorders
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer en metode for behandling, forbedring eller forebygging av en neurodegenerativ lidelse hos en pasient med behov for dette som omfatter administrering til nevnte pasient av en effektiv mengde av en 5-hydroksytryptamin-6-agonist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63576604P | 2004-12-14 | 2004-12-14 | |
PCT/US2005/044820 WO2006065710A1 (en) | 2004-12-14 | 2005-12-12 | Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073104L true NO20073104L (no) | 2007-07-02 |
Family
ID=36177731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073104A NO20073104L (no) | 2004-12-14 | 2007-06-18 | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060128744A1 (no) |
EP (1) | EP1824464A1 (no) |
JP (1) | JP2008523146A (no) |
KR (1) | KR20070088770A (no) |
CN (1) | CN101098683A (no) |
AU (1) | AU2005316675A1 (no) |
BR (1) | BRPI0519036A2 (no) |
CA (1) | CA2590841A1 (no) |
CR (1) | CR9200A (no) |
IL (1) | IL183859A0 (no) |
MX (1) | MX2007007206A (no) |
NO (1) | NO20073104L (no) |
RU (1) | RU2007122450A (no) |
WO (1) | WO2006065710A1 (no) |
ZA (1) | ZA200705083B (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
JP2005305107A (ja) * | 2004-03-25 | 2005-11-04 | Sei Matsuoka | 価値的情報値の測定装置およびこれを使用した測定方法 |
CA2651732C (en) | 2006-05-18 | 2014-10-14 | Mannkind Corporation | Intracellular kinase inhibitors |
EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
CN104557664B (zh) * | 2013-10-19 | 2020-01-21 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
CN1309385C (zh) * | 2001-12-20 | 2007-04-11 | 惠氏公司 | 作为5-羟色胺-6配体的吲哚基烷基胺衍生物 |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
-
2005
- 2005-12-12 CA CA002590841A patent/CA2590841A1/en not_active Abandoned
- 2005-12-12 EP EP05853687A patent/EP1824464A1/en not_active Withdrawn
- 2005-12-12 JP JP2007546799A patent/JP2008523146A/ja not_active Withdrawn
- 2005-12-12 WO PCT/US2005/044820 patent/WO2006065710A1/en active Application Filing
- 2005-12-12 CN CNA2005800464202A patent/CN101098683A/zh not_active Withdrawn
- 2005-12-12 RU RU2007122450/14A patent/RU2007122450A/ru not_active Application Discontinuation
- 2005-12-12 MX MX2007007206A patent/MX2007007206A/es unknown
- 2005-12-12 BR BRPI0519036-3A patent/BRPI0519036A2/pt not_active IP Right Cessation
- 2005-12-12 KR KR1020077015556A patent/KR20070088770A/ko not_active Application Discontinuation
- 2005-12-12 AU AU2005316675A patent/AU2005316675A1/en not_active Abandoned
- 2005-12-13 US US11/301,445 patent/US20060128744A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183859A patent/IL183859A0/en unknown
- 2007-06-13 ZA ZA200705083A patent/ZA200705083B/xx unknown
- 2007-06-18 NO NO20073104A patent/NO20073104L/no not_active Application Discontinuation
- 2007-06-20 CR CR9200A patent/CR9200A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1824464A1 (en) | 2007-08-29 |
US20060128744A1 (en) | 2006-06-15 |
CN101098683A (zh) | 2008-01-02 |
IL183859A0 (en) | 2008-12-29 |
AU2005316675A1 (en) | 2006-06-22 |
CR9200A (es) | 2007-09-07 |
MX2007007206A (es) | 2008-03-26 |
BRPI0519036A2 (pt) | 2008-12-23 |
RU2007122450A (ru) | 2009-01-27 |
KR20070088770A (ko) | 2007-08-29 |
ZA200705083B (en) | 2010-03-31 |
CA2590841A1 (en) | 2006-06-22 |
WO2006065710A1 (en) | 2006-06-22 |
JP2008523146A (ja) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
NO20073104L (no) | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser | |
DK1742624T3 (da) | Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
DK1809280T3 (da) | Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf | |
AU2003256755A8 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
EA200971053A1 (ru) | Способы лечения кожных язв | |
NO20082894L (no) | Metode for behandling av kognitiv dysfunksjon | |
JO3358B1 (ar) | معالجات حساسية العيون | |
NO20052999L (no) | Ny synergistisk kombinasjon omfattende roflumilast og formoterol | |
WO2008016640A3 (en) | Use of poloxamer for the prevention and/or treatment of heart failure | |
EA200901062A1 (ru) | Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств | |
DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
NO20045343L (no) | Ny kombinasjon for behandling av luftveisforstyrrelser | |
NO20073610L (no) | Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase | |
BR112022003918A2 (pt) | Rebamipida para uso na prevenção e tratamento da doença de crohn | |
EA200901145A1 (ru) | Применение рибофлавина в лечении гипертензии | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
DK1503764T3 (da) | 5-HT4-receptor-antagonister til behandling af hjertesvigt | |
BR0316475A (pt) | Combinação sinergìstica que compreende roflumilast e (r,r)-formoterol | |
NO20045344L (no) | Kombinasjon for behandling av luftveisforstyrrelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |